Description
PT-141, also known as bremelanotide, is a synthetic peptide derived from melanotan II that activates melanocortin receptors in the brain. It works by stimulating central pathways involved in sexual desire, and it has been shown in clinical trials to improve sexual function in both men and women. In women, it is FDA-approved for treating hypoactive sexual desire disorder. Common side effects include nausea, flushing, and headaches, and it acts quickly, with effects starting around 30 minutes after use.
PT-141 / Bremelanotide Research Details
PT-141 (bremelanotide) is a melanocortin analog derived from melanotan-II research. Literature describes receptor-selective signaling at melanocortin receptors and central pathway biology. OneBio content is restricted to research-use discussion only.
99%+ target purity or lot-specific COA value
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Lyophilized research material unless otherwise specified by COA
Research use only
Research Background
Cyclic melanocortin-receptor agonist studied for central melanocortin pathway pharmacology, especially MC3R/MC4R signaling. Key OneBio research contexts include melanocortin receptor assays, mc4r/mc3r pharmacology, receptor selectivity work, and neuroendocrine pathway research.
Specifications
| Compound | PT-141 / Bremelanotide |
| SKU / Product | pt-141 |
| Molecular Weight | ~1025.2 g/mol |
| Formula / Classification | C50H68N14O10 |
| Database / Identity Note | PubChem CID 9941379 |
| Storage | -4°F long-term; 35-46°F short-term refrigerated; 39°F after reconstitution for up to 30 days when appropriate for the research protocol |
Quality Verification
Each batch should be reviewed against its Certificate of Analysis, including identity confirmation, purity method, mass/sequence or component confirmation, appearance, and lot-specific handling notes. Blend products should be checked against component-ratio documentation where available.
Laboratory Preparation
Prepare only inside a qualified laboratory using validated solvent choice, concentration, sterility, and storage protocols. For lyophilized peptides, use sterile deionized water or bacteriostatic water when appropriate for the research protocol, mix gently, maintain cold-chain handling, and avoid repeated freeze-thaw cycles.
Product-Specific Q&A
What is PT-141 / Bremelanotide used for in research?
PT-141 / Bremelanotide is used as a research material for melanocortin receptor assays, mc4r/mc3r pharmacology, receptor selectivity work, and neuroendocrine pathway research. It is not offered for diagnostic, therapeutic, clinical, veterinary, or human-use applications.
What mechanism is most relevant for PT-141 / Bremelanotide?
Cyclic melanocortin-receptor agonist studied for central melanocortin pathway pharmacology, especially MC3R/MC4R signaling.
How should PT-141 / Bremelanotide identity and purity be verified?
Use the lot-specific Certificate of Analysis to confirm identity, purity, mass/sequence or component profile, and any method-specific data such as LC-MS/HPLC. Technical values on this page are research references and should be checked against the delivered lot.
What storage conditions apply to PT-141 / Bremelanotide?
-4°F long-term; 35-46°F short-term refrigerated; 39°F after reconstitution for up to 30 days when appropriate for the research protocol. Keep sealed, dry, protected from light, and avoid repeated freeze-thaw cycles after preparation.
References
- PMID 15134289: PT-141 Palatin. Current opinion in investigational drugs (London, England : 2000) 2004.
- PMID 31429064: Bremelanotide: First Approval. Drugs 2019.
- PMID 37365323: Targeting the central melanocortin system for the treatment of metabolic disorders. Nature reviews. Endocrinology 2023.

Reviews
There are no reviews yet.